JP2009533338A - 置換環縮合アジンおよび癌治療におけるそれらの使用 - Google Patents

置換環縮合アジンおよび癌治療におけるそれらの使用 Download PDF

Info

Publication number
JP2009533338A
JP2009533338A JP2009504144A JP2009504144A JP2009533338A JP 2009533338 A JP2009533338 A JP 2009533338A JP 2009504144 A JP2009504144 A JP 2009504144A JP 2009504144 A JP2009504144 A JP 2009504144A JP 2009533338 A JP2009533338 A JP 2009533338A
Authority
JP
Japan
Prior art keywords
benzofuran
dimethyl
quinazolinyl
propanediamine
dihydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009504144A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009533338A5 (enExample
Inventor
ウィリアム アレキサンダー デニー
ブルース チャールズ バグリー
エレイン シャーリー マーシャル
ハミッシュ スコット サザーランド
Original Assignee
オークランド ユニサーヴィスィズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オークランド ユニサーヴィスィズ リミテッド filed Critical オークランド ユニサーヴィスィズ リミテッド
Publication of JP2009533338A publication Critical patent/JP2009533338A/ja
Publication of JP2009533338A5 publication Critical patent/JP2009533338A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2009504144A 2006-04-07 2007-04-04 置換環縮合アジンおよび癌治療におけるそれらの使用 Pending JP2009533338A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ546477A NZ546477A (en) 2006-04-07 2006-04-07 4-Alkylamino-2-(heterocyclic)quinazolines and their use in cancer therapy
PCT/NZ2007/000077 WO2007117161A1 (en) 2006-04-07 2007-04-04 Substituted ring fused azines and their use in cancer therapy

Publications (2)

Publication Number Publication Date
JP2009533338A true JP2009533338A (ja) 2009-09-17
JP2009533338A5 JP2009533338A5 (enExample) 2010-05-06

Family

ID=38581368

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009504144A Pending JP2009533338A (ja) 2006-04-07 2007-04-04 置換環縮合アジンおよび癌治療におけるそれらの使用

Country Status (8)

Country Link
US (1) US20090318479A1 (enExample)
EP (1) EP2004637A4 (enExample)
JP (1) JP2009533338A (enExample)
CN (1) CN101460490A (enExample)
AU (1) AU2007235751A1 (enExample)
CA (1) CA2648323A1 (enExample)
NZ (1) NZ546477A (enExample)
WO (1) WO2007117161A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017533215A (ja) * 2014-10-29 2017-11-09 ドン−ア エスティ カンパニー リミテッド ヒストンリジン脱メチル化触媒活性を調節するための新規ピリドピリミジノン化合物

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012046207A1 (en) * 2010-10-08 2012-04-12 Paraco Technology Limited Anti-parasitic substituted ring fused azine compounds
US8710064B2 (en) * 2011-10-20 2014-04-29 China Medical University 2-aryl-4-quinazolinones and their pharmaceutical compositions
KR20150016406A (ko) 2012-06-07 2015-02-11 에프. 호프만-라 로슈 아게 탄키라제의 피라졸로피리미돈 및 피라졸로피리돈 억제제
WO2013182580A1 (en) 2012-06-07 2013-12-12 F. Hoffmann-La Roche Ag Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase
WO2014143609A1 (en) 2013-03-11 2014-09-18 Bristol-Myers Squibb Company Isoquinolines as potassium ion channel inhibitors
CN105916506B (zh) 2013-11-20 2020-01-07 圣诺康生命科学公司 作为tam家族激酶抑制剂的喹唑啉衍生物
US20170057955A1 (en) * 2015-08-26 2017-03-02 Dong-A Socio Holdings Co., Ltd. Pyridopyrimidinone Compounds for Modulating the Catalytic Activity of Histone Lysine Demethylases (KDMs)
CN107721982B (zh) * 2017-10-16 2019-12-03 中山大学 一种抗肥胖症化合物及其制备方法和应用
CN110483394A (zh) * 2019-09-02 2019-11-22 广东工业大学 一种化合物的应用
CN113072543B (zh) * 2020-01-03 2022-07-22 南方医科大学 一种2-芳杂环基喹唑啉酮类化合物及其制备方法和用途
WO2021155426A1 (en) * 2020-02-04 2021-08-12 TroBio Therapeutics Pty Ltd Quinazoline compounds and the use thereof in the treatment of cancer
WO2022061224A1 (en) 2020-09-21 2022-03-24 Landos Biopharma, Inc. Nlrx1 ligands
CN114044769B (zh) * 2021-11-25 2023-12-12 中山大学 一种β-吲哚喹唑啉酮衍生物及其制备方法和应用
CN117247374A (zh) * 2022-06-10 2023-12-19 成都先导药物开发股份有限公司 一种bcl-xl抑制剂及其制药用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3897432A (en) * 1971-04-21 1975-07-29 Merck & Co Inc Substituted benzimidazole derivatives
EP1088818A1 (en) * 1999-10-01 2001-04-04 F. Hoffmann-La Roche Ag Quinolin-4-yl derivatives
WO2001083456A1 (en) * 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Condensed heteroaryl derivatives
US20020048271A1 (en) * 1998-12-02 2002-04-25 Farzan Rastinejad Methods and composition for restoring conformational stability of a protein of the p53 family
WO2002062767A1 (en) * 2001-02-07 2002-08-15 Sumitomo Pharmaceuticals Company, Limited Novel quinazoline derivatives

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3897432A (en) * 1971-04-21 1975-07-29 Merck & Co Inc Substituted benzimidazole derivatives
US20020048271A1 (en) * 1998-12-02 2002-04-25 Farzan Rastinejad Methods and composition for restoring conformational stability of a protein of the p53 family
EP1088818A1 (en) * 1999-10-01 2001-04-04 F. Hoffmann-La Roche Ag Quinolin-4-yl derivatives
WO2001083456A1 (en) * 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Condensed heteroaryl derivatives
WO2002062767A1 (en) * 2001-02-07 2002-08-15 Sumitomo Pharmaceuticals Company, Limited Novel quinazoline derivatives

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6012040350; ＬＥＥ，Ｅ．Ｓ．　ｅｔ　ａｌ: 'Ｓｙｎｔｈｅｓｉｓ　ａｎｄ　ｂｉｏｌｏｇｉｃａｌ　ｐｒｏｐｅｒｔｉｅｓ　ｏｆ　ｓｅｌｅｃｔｅｄ　２-ａｒｙｌ-４（３Ｈ）-ｑｕｉｎａｚｏｌｉｎｏｎｅｓ' Ｈｅｔｅｒｏｃｙｃｌｉｃ　Ｃｏｍｍｕｎｉｃａｔｉｏｎｓ Ｖｏｌ．１０，　Ｎｏ．４-５, 2004, ｐ．３２５-３３０ *
JPN6012040352; ＳＵＩ，Ｚ．　ｅｔ　ａｌ: 'Ｓｙｎｔｈｅｓｉｓ　ｏｆ　２-ｓｕｂｓｔｉｔｕｔｅｄ　４-ｑｕｉｎａｚｏｌｏｎｅ-５-ｃａｒｂｏｘｙｌｉｃ　ａｃｉｄｓ　ａｓ　ｉｎｈｉｂｉｔｏｒｓ　ｏｆ　ＤＮＡ-ｇｙｒａｓｅ' Ｊｏｕｒｎａｌ　ｏｆ　Ｈｅｔｅｒｏｃｙｃｌｉｃ　Ｃｈｅｍｉｓｔｒｙ Ｖｏｌ．３４，　Ｎｏ．１, 1997, ｐ．１５３-１５６ *
JPN6012040354; ＨＥＲＭＥＣＺ，Ｉ．　ｅｔ　ａｌ: 'Ｓｙｎｔｈｅｓｅｓ　ｏｆ　ｉｎｄｏｌｙｌ-４（３Ｈ）-ｑｕｉｎａｚｏｌｉｎｏｎｅｓ' Ｈｅｔｅｒｏｃｙｃｌｅｓ Ｖｏｌ．３７，　Ｎｏ．２, 1994, ｐ．９０３-１４ *
JPN6012040357; ＬＡＬ，Ｂ．　ｅｔ　ａｌ: 'Ａ　ｎｏｖｅｌ　ｂａｓｅ-ｃａｔａｌｙｚｅｄ　ｃａｒｂｏｎ-ｎｉｔｒｏｇｅｎ　ｂｏｎｄ　ｆｉｓｓｉｏｎ　ｉｎ　ｓｏｍｅ　ｈｅｔｅｒｏｃｙｃｌｅｓ' Ｊｏｕｒｎａｌ　ｏｆ　Ｏｒｇａｎｉｃ　Ｃｈｅｍｉｓｔｒｙ Ｖｏｌ．５５，　Ｎｏ．１７, 1990, ｐ．５１１７-２４ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017533215A (ja) * 2014-10-29 2017-11-09 ドン−ア エスティ カンパニー リミテッド ヒストンリジン脱メチル化触媒活性を調節するための新規ピリドピリミジノン化合物

Also Published As

Publication number Publication date
CN101460490A (zh) 2009-06-17
CA2648323A1 (en) 2007-10-18
US20090318479A1 (en) 2009-12-24
NZ546477A (en) 2009-04-30
AU2007235751A1 (en) 2007-10-18
EP2004637A1 (en) 2008-12-24
EP2004637A4 (en) 2010-11-03
WO2007117161A1 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
JP2009533338A (ja) 置換環縮合アジンおよび癌治療におけるそれらの使用
US12129236B2 (en) PARG inhibitory compounds
US10717711B2 (en) Amino quinazolines as kinase inhibitors
JP4848286B2 (ja) 複素環アミド化合物及びｍｍｐ−１３阻害剤としてのその用途
AU2012339640B2 (en) Uracil derivatives as AXL and c-MET kinase inhibitors
Ohashi et al. Discovery of pyrrolo [3, 2-c] quinoline-4-one derivatives as novel hedgehog signaling inhibitors
US20030207883A1 (en) Indazole benzimidazole compounds
US11535598B2 (en) Histone deacetylases (HDACs) inhibitors
WO2009084695A1 (ja) ２－アミノキナゾリン誘導体
WO2009077956A2 (ru) ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Нh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ
BRPI0618668B1 (pt) Compostos inibidores dos receptores de tirosina quinase do tipo i, composições compreendendo tais compostos, e seus usos
PL211125B1 (pl) Pochodne chinolinonu jako inhibitory kinazy tyrozynowej, kompozycje je zawierające i ich zastosowanie
JP2006520397A (ja) 新規融合トリアゾロン類及びその使用
WO2003055492A1 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
WO2013013614A1 (zh) 4-(3-杂芳基芳基氨基)喹唑啉和1-(3-杂芳基芳基氨基)异喹啉作为Hedgehog通路抑制剂及其应用
EP1228043B1 (en) Isoquinoline and quinazoline deivatives having a combined 5ht1a, 5ht1b and 5ht1d receptor activity
US9643968B2 (en) Fused acridine derivative and pharmaceutical composition, preparation method and use thereof
TW202416958A (zh) 用於抑制yap-tead交互作用的新穎雜雙環化合物及包含其之藥學組成物
HK1202528B (en) Uracil derivatives as axl and c-met kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100309

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100309

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100309

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120807

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130205